Drugs / INCA034176
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06843408 | Jun 2025 → Jul 2026 overdue | chronic graft versus host disease | Incyte Corporation | Recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06821542 | Jun 2025 → May 2028 expected | chronic graft versus host disease | Incyte Corporation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06585774 | Jan 2025 → Sep 2027 expected | chronic graft versus host disease | Incyte Corporation | Recruiting | No outcome recorded |
| Phase 3 | NCT06263478 | Jul 2024 → Aug 2025 overdue | chronic graft versus host disease | Incyte Biosciences Japan GK | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INCA034176 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06585774 ↗ |
| Route | Intravenous | “IV infusion” NCT06263478 ↗ |